"Pfizer is the first big pharmaceutical company to reach an agreement with the Trump administration over most-favored nation drug pricing, a deal that lowers U.S. prices of certain medications and makes them available directly to patients through new online channels. The agreement announced Tuesday also gives Pfizer a grace period before facing potential tariffs on its drugs. With most-favored nation pricing, the prices of a drug in the U.S. will be matched to the lowest price of the same drug in a comparable developed nation."
"In a Tuesday news conference with the Trump administration, Pfizer executives said the company will participate in TrumpRx.gov, a new purchasing platform that will allow Americans to purchase most primary care treatments and certain specialty drugs from Pfizer "at a significant discount." A White House fact sheet listed some examples of existing Pfizer products: an 80% discount for atopic dermatitis drug Eucrisa; a 40% discount for immunology drug Xeljanz; and a 50% discount for migraine drug Zavpret."
"Specific terms of the agreement remain confidential. But the White House said the agreement means every state Medicaid program in the country will have access to most-favored nation drug prices on Pfizer products. Furthermore, the agreement secures most-favored nation pricing on all new drugs Pfizer brings to the market. As the deadline for a response to Trump's most-favored nation proposal approached, pharma companies rolled out initiatives that could help them meet the goals outlined in the executive order."
Pfizer reached an agreement with the Trump administration to implement most-favored nation drug pricing that lowers U.S. prices for certain medications and provides a grace period before potential tariffs. Most-favored nation pricing requires matching U.S. drug prices to the lowest prices in comparable developed countries. Pfizer will sell many primary-care and some specialty drugs through TrumpRx.gov at significant discounts, with cited examples including large reductions for Eucrisa, Xeljanz, and Zavpret. The deal grants every state Medicaid program access to these prices and secures most-favored nation pricing for future Pfizer drugs. Specific contractual terms remain confidential.
Read at MedCity News
Unable to calculate read time
Collection
[
|
...
]